Shares & Derivatives
Hyphens Pharma (1J5): Undervalued Proxy to ASEAN Pharmaceuticals | Current: S$0.20 | Target: S$0.29 | Upside: +45% |
By My Route To Financial Freedom  •  August 14, 2019

Hi everyone,

My team comprising of Bryan, Jin Koi and I are participating in the Investor-One Stock Pitch Challenge 2019 under the team name Prinsep Capital. Out of the 220 SGX-Catalist stocks,  we had to pick a stock to initiate a Buy call on. After conducting various screenings and understanding the story of various Catalist counters, Hyphens Pharma stood out to us as one of the most high-quality undervalued and undercovered stock which we believe has significant upside potential. Please do give it a read as we have work on it tirelessly over the past two months.

You can download our research report here: Hyphens Pharma Prinsep Capital

Do show us your support by voting for us, Prinsep Capital. The top six teams with the highest number of votes will make it into the finals where we would be pitching the company in front of a judging panel. We hope you

...
Read the full article
By My Route To Financial Freedom
Aloysius Lee, co-founder, is currently pursuing a degree in Business at Nanyang Technological University (NTU) and is the President of Investment Interactive Club 17/18. He graduated from Singapore Polytechnic (SP) with a Diploma in Banking and Financial Services. During his course of study, he was awarded the SB Business School Achiever Award, UOB Kay Hian Scholarship and Phillip Futures Prize ...
LEAVE A COMMENT
LEAVE A COMMENT

Your email address will not be published.

*

Your Email Address will not be published
*

Read More Articles
More from thefinance